Xconomy’s Digital Events →
Akero’s FGF21 analog yields 63 percent to 72 percent relative hepatic fat reduction in Phase 2a study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says... Read more »
From Our Partners · Special Report
Advice for funding and future transformational opportunities
From Our Editors · Podcast
Becoming the Cell & Gene Therapy Hub
Sponsored · Whitepaper
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
© 2007-2021, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.